GSTM1 and chronic kidney disease: Finally, recently, a systematic review and meta-analysis including 10 different RCTs and 5,698 DD-CKD patients revealed that compared to the ESAs group, the roxadustat group showed increased Hb levels (95%CI, 0.14 to 0.36; P < 0.00001).